Terns Pharmaceuticals (TERN) Stock Forecast & Price Target

Compare

497 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TERN Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Terns

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TERN Stock 12 Month Forecast

Average Price Target

$53.75

▲(56.02% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Terns Pharmaceuticals in the last 3 months. The average price target is $53.75 with a high forecast of $60.00 and a low forecast of $35.00. The average price target represents a 56.02% change from the last price of $34.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","46":"$46","61":"$61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,16,31,46,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.4,41.90769230769231,43.41538461538462,44.92307692307692,46.43076923076923,47.93846153846154,49.44615384615385,50.95384615384616,52.46153846153846,53.96923076923077,55.47692307692308,56.98461538461538,58.49230769230769,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.4,41.426923076923075,42.45384615384615,43.480769230769226,44.50769230769231,45.534615384615385,46.56153846153846,47.58846153846154,48.61538461538461,49.642307692307696,50.669230769230765,51.69615384615385,52.723076923076924,{"y":53.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.4,39.98461538461538,39.56923076923077,39.15384615384615,38.738461538461536,38.323076923076925,37.90769230769231,37.49230769230769,37.07692307692307,36.66153846153846,36.246153846153845,35.83076923076923,35.41538461538462,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$53.75

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andy Hsieh

William Blair

Buy

―

Reiterated

01/13/26

TERN-701’s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals

Evan Seigerman

BMO Capital

$54

Buy

56.75%

Upside

Reiterated

01/12/26

De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals

Etzer Darout

Barclays

$56

Buy

62.55%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (NASDAQ: AVR) and Terns Pharmaceuticals (NASDAQ: TERN)

Srikripa Devarakonda

Truist Financial

$56

Buy

62.55%

Upside

Reiterated

01/08/26

Truist Financial Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)

Graig Suvannavejh

Mizuho Securities

$54

Buy

56.75%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (NASDAQ: TERN), Qiagen (NYSE: QGEN) and Standard BioTools (NASDAQ: LAB)

Silvan Tuerkcan

Citizens JMP

$35→$57

Buy

65.46%

Upside

Reiterated

12/11/25

Terns Pharmaceuticals price target raised to $57 from $35 at CitizensTerns Pharmaceuticals price target raised to $57 from $35 at Citizens

Andres Y. Maldonado

H.C. Wainwright

$20→$60

Buy

74.17%

Upside

Reiterated

12/09/25

Terns Pharmaceuticals price target raised to $60 from $20 at H.C. WainwrightTerns Pharmaceuticals price target raised to $60 from $20 at H.C. Wainwright

Jay Olson

Oppenheimer

$28→$58

Buy

68.36%

Upside

Reiterated

12/09/25

Terns Pharmaceuticals price target raised to $58 from $28 at OppenheimerTerns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer

Akash Tewari

Jefferies

$35

Buy

1.60%

Upside

Reiterated

12/08/25

Terns Pharmaceuticals (TERN) Gets a Buy from Jefferies

Ritu Baral

TD Cowen

Buy

―

Reiterated

11/13/25

Terns Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$15

Buy

-56.46%

Downside

Initiated

09/17/25

Terns Pharmaceuticals (TERN) Gets a Buy from Roth MKM

Eliana Merle

UBS

$17

Buy

-50.65%

Downside

Reiterated

09/15/25

Anticipated Data Updates and Underappreciated Catalysts Drive Buy Rating for Terns Pharmaceuticals

Eric Joseph

J.P. Morgan

$14

Hold

-59.36%

Downside

Reiterated

05/09/25

J.P. Morgan Remains a Hold on Terns Pharmaceuticals (TERN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andy Hsieh

William Blair

Buy

―

Reiterated

01/13/26

TERN-701’s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals

Evan Seigerman

BMO Capital

$54

Buy

56.75%

Upside

Reiterated

01/12/26

De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals

Etzer Darout

Barclays

$56

Buy

62.55%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (NASDAQ: AVR) and Terns Pharmaceuticals (NASDAQ: TERN)

Srikripa Devarakonda

Truist Financial

$56

Buy

62.55%

Upside

Reiterated

01/08/26

Truist Financial Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)

Graig Suvannavejh

Mizuho Securities

$54

Buy

56.75%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (NASDAQ: TERN), Qiagen (NYSE: QGEN) and Standard BioTools (NASDAQ: LAB)

Silvan Tuerkcan

Citizens JMP

$35→$57

Buy

65.46%

Upside

Reiterated

12/11/25

Terns Pharmaceuticals price target raised to $57 from $35 at CitizensTerns Pharmaceuticals price target raised to $57 from $35 at Citizens

Andres Y. Maldonado

H.C. Wainwright

$20→$60

Buy

74.17%

Upside

Reiterated

12/09/25

Terns Pharmaceuticals price target raised to $60 from $20 at H.C. WainwrightTerns Pharmaceuticals price target raised to $60 from $20 at H.C. Wainwright

Jay Olson

Oppenheimer

$28→$58

Buy

68.36%

Upside

Reiterated

12/09/25

Terns Pharmaceuticals price target raised to $58 from $28 at OppenheimerTerns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer

Akash Tewari

Jefferies

$35

Buy

1.60%

Upside

Reiterated

12/08/25

Terns Pharmaceuticals (TERN) Gets a Buy from Jefferies

Ritu Baral

TD Cowen

Buy

―

Reiterated

11/13/25

Terns Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$15

Buy

-56.46%

Downside

Initiated

09/17/25

Terns Pharmaceuticals (TERN) Gets a Buy from Roth MKM

Eliana Merle

UBS

$17

Buy

-50.65%

Downside

Reiterated

09/15/25

Anticipated Data Updates and Underappreciated Catalysts Drive Buy Rating for Terns Pharmaceuticals

Eric Joseph

J.P. Morgan

$14

Hold

-59.36%

Downside

Reiterated

05/09/25

J.P. Morgan Remains a Hold on Terns Pharmaceuticals (TERN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Terns Pharmaceuticals

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+34.99%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +34.99% per trade.

1 Year

Ritu BaralTD Cowen

Success Rate

8/14 ratings generated profit

Average Return

+183.59%

reiterated a buy rating 2 months ago

Copying Ritu Baral's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +183.59% per trade.

2 Years

xxx

Success Rate

12/14 ratings generated profit

Average Return

+347.32%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +347.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TERN Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TERN has received 34 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TERN average Analyst price target in the past 3 months is 53.75.

Each month's total comprises the sum of three months' worth of ratings.

TERN Financial Forecast

TERN Earnings Forecast

Next quarter’s earnings estimate for TERN is -$0.30 with a range of -$0.40 to -$0.22. The previous quarter’s EPS was -$0.27. TERN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TERN has Performed in-line its overall industry.

No data currently available

TERN Sales Forecast

Next quarter’s sales forecast for TERN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TERN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TERN has Performed in-line its overall industry.

TERN Stock Forecast FAQ

What is TERN’s average 12-month price target, according to analysts?

Based on analyst ratings, Terns Pharmaceuticals’s 12-month average price target is 53.75.

What is TERN’s upside potential, based on the analysts’ average price target?

Terns Pharmaceuticals has 56.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TERN a Buy, Sell or Hold?

Terns Pharmaceuticals has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Terns Pharmaceuticals’s price target?

The average price target for Terns Pharmaceuticals is 53.75. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $35.00. The average price target represents 56.02% Increase from the current price of $34.45.

What do analysts say about Terns Pharmaceuticals?

Terns Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of TERN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Terns Pharmaceuticals (TERN) Stock Forecast & Price Target

TERN Analyst Ratings

TERN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Terns Pharmaceuticals

TERN Analyst Recommendation Trends

TERN Financial Forecast

TERN Earnings Forecast

TERN Sales Forecast

TERN Stock Forecast FAQ

Detailed List of Analyst Forecasts